Pfizer in advanced talks to buy global blood therapeutics for about $5 billion2 min read . Updated: 06 Aug 2022, 01:49 PM IST
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer Inc. is in advanced talks to buy Global Blood Therapeutics Inc., the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more